Does placebo response differ between objective and subjective measures in children with attention-deficit/hyperactivity disorder?

Postgraduate Medicine

Volumn 122, Issue 5, 2010, Pages 52-61

  Sumner, Calvin R ^a,b   Haynes, Virginia S ^c   Teicher, Martin H ^d,e   Newcorn, Jeffrey H ^f  

^a BioBehavioral Diagnostics Company   (United States)

^b BioBehavioral Diagnostics Company   (United States)

^c i3 Global   (Canada)

^d HARVARD MEDICAL SCHOOL   (United States)

^e MCLEAN HOSPITAL   (United States)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

ADHD; Adolescent; Assessment; Child; Placebo; Treatment outcome

Indexed keywords

ATOMOXETINE; METHYLPHENIDATE; PLACEBO; ADRENERGIC RECEPTOR AFFECTING AGENT; CENTRAL STIMULANT AGENT; PROPYLAMINE;

ADHD RATING SCALE; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSIONS OF ADHD SEVERITY SCALE; COMPUTER SYSTEM; CONNERS PARENT RATING SCALE REVISED SHORT FORM; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CORRELATION COEFFICIENT; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; HUMAN; INTERMETHOD COMPARISON; INTERVIEW; MALE; NEUROPSYCHOLOGICAL TEST; PILOT STUDY; PLACEBO EFFECT; QUOTIENT GLOBAL SCALED SCORE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHOOL CHILD; SCORING SYSTEM; SENSITIVITY ANALYSIS; ADOLESCENT; CLINICAL TRIAL; DELAYED RELEASE FORMULATION; DOSE RESPONSE; HOSPITALIZATION;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; METHYLPHENIDATE; NEUROPSYCHOLOGICAL TESTS; PLACEBO EFFECT; PROPYLAMINES; SEVERITY OF ILLNESS INDEX;

EID: 78049510934     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2010.09.2201     Document Type: Article

References (61)

1. Flint A. A contribution toward the natural history of articular rheumatism, consisting of a report of thirteen cases treated solely with palliative measures. Am J Med Sci. 1863;46:17-36.
2. Jellinek EM. Clinical tests on comparative effectiveness of analgesic drugs. Biometrics. 1946;2:87-91.
3. Lilienfeld AM. The Fielding H. Garrison Lecture: Ceteris paribus: the evolution of the clinical trial. Bull Hist Med. 1982;56:1-18.
4. Temple R, Ellenberg SS. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues. Ann Intern Med. 2000;133(6):455-463.
5. Emanuel EJ, Miller FG. The ethics of placebo-controlled trials: a middle ground. N Engl J Med. 2001;345(12):915-919.
6. Thompson WG. Placebos: a review of the placebo response. Am J Gastroenterol. 2000;95(7):1637-1643.
7. Rothman KJ, Michels KB. The continuing unethical use of placebo controls. N Engl J Med. 1994;331(6):394-398.
8. Rothman KJ. Declaration of Helsinki should be strengthened. BMJ. 2000;321(7258):442-445.
9. Enserink M. Bioethics. Helsinki's new clinical rules: fewer placebos, more disclosure. Science. 2000;290(5491):418-419.
10. Bienenfeld L, Frishman W, Glasser SP. The placebo effect in cardiovascular disease. Am Heart J. 1996;132(6):1207-1221.
11. World Medical Association. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. http://wwwwma net/en/30publications/10policies/b3/17c pdf. Accessed July 23, 2010.
12. Cocco G. Erectile dysfunction after therapy with metoprolol: the Hawthorne effect. Cardiology. 2009;112(3):174-177.
13. Khan A, Schwartz K. Design features that affect psychopharmacology trials. Lett Drug Design Discovery. 2005;2:546-550.
14. Ellenberg SS, Temple R. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: practical issues and specific cases. Ann Intern Med. 2000;133(6):464-470.
15. Waschbusch DA, Pelham WE Jr, Waxmonsky J, Johnston C. Are there placebo effects in the medication treatment of children with attention-deficit hyperactivity disorder? J Dev Behav Pediatr. 2009;30(2):158-168.
16. Price DD, Finniss DG, Benedetti F. A comprehensive review of the placebo effect: recent advances and current thought. Annu Rev Psychol. 2008;59:565-590.
17. Koshi EB, Short CA. Placebo theory and its implications for research and clinical practice: a review of the recent literature. Pain Pract. 2007;7:4-20.
18. Sandler A. Placebo effects in developmental disabilities: implications for research and practice. Ment Retard Dev Disabil Res Rev. 2005;11(2):164-170.
19. Khan A, Kolts RL, Rapaport MH, Krishnan KR, Brodhead AE, Browns WA. Magnitude of placebo response and drug-placebo differences across psychiatric disorders. Psychol Med. 2005;35(5):743-749.
20. Khan A, Bhat A, Kolts R, Thase ME, Brown W. Why has the antidepressant-placebo difference in antidepressant clinical trials diminished over the past three decades? CNS Neurosci Ther. 2010;16(4):217-226.
21. Fava M, Evins AE, Dorer DJ, Schoenfeld DA. The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother Psychosom. 2003;72(3):115-127.
22. Kemp AS, Schooler NR, Kalali AH, et al. What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it? Schizophr Bull. 2010;36(3):504-509.
23. Sandler AD, Glesne CE, Bodfish JW. Conditioned placebo dose reduction: a new treatment in attention-deficit hyperactivity disorder? J Dev Behav Pediatr. 2010;31(5):369-375.
24. Faraone SV, Short EJ, Biederman J, Findling RL, Roe C, Manos MJ. Efficacy of Adderall and methylphenidate in attention deficit hyperactivity disorder: a drug-placebo and drug-drug response curve analysis of a naturalistic study. Int J Neuropsychopharmacol. 2002;5(2):121-129.
25. Mikami AY, Calhoun CD, Abikoff HB. Positive illusory bias and response to behavioral treatment among children with attention-deficit/hyperactivity disorder. J Clin Child Adolesc Psychol. 2010;39(3):373-385.
26. Rheims S, Cucherat M, Arzimanoglou A, Ryvlin P. Greater response to placebo in children than in adults: a systematic review and meta-analysis in drug-resistant partial epilepsy. PLoS Med. 2008;5(8):e166.
27. Birmaher B, Brent D; AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry. 2007;46(11):1503-1526.
28. MTA Cooperative Group. Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder: the Multimodal Treatment Study of children with Attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 1999;56(12):1088-1096.
29. Schachar RJ, Tannock R, Cunningham C, Corkum PV. Behavioral, situational, and temporal effects of treatment of ADHD with methylphenidate. J Am Acad Child Adolesc Psychiatry. 1997;36(6):754-763.
30. Newcorn JH, Sutton VK, Zhang S, et al. Characteristics of placebo responders in pediatric clinical trials of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2009;48(12):1165-1172.
31. Batzle CS, Weyandt LL, Janusis GM, Devietti TL. Potential impact of ADHD with stimulant medication label on teacher expectations [published online ahead of print September 22, 2009]. J Atten Disord.
32. Johnston C, Ohan JL. The importance of parental attributions in families of children with attention-deficit/hyperactivity and disruptive behavior disorders. Clin Child Fam Psychol Rev. 2005;8(3):167-182.
33. Collett BR, Gimpel GA. Maternal and child attributions in ADHD versus non-ADHD populations. J Atten Disord. 2004;7(4):187-196.
34. Johnston C, Fine S, Weiss M, Weiss J, Weiss G, Freeman WS. Effects of stimulant medication treatment on mothers' and children's attributions for the behavior of children with attention deficit hyperactivity disorder. J Abnorm Child Psychol. 2000;28(4):371-382.
35. Johnston C, Reynolds S, Freeman WS, Geller J. Assessing parent attributions for child behavior using open-ended questions. J Clin Child Psychol. 1998;27(1):87-97.
36. Edwards MC, Gardner ES, Chelonis JJ, Schulz EG, Flake RA, Diaz PF. Estimates of the validity and utility of the Conners' Continuous Performance Test in the assessment of inattentive and/or hyperactive-impulsive behaviors in children. J Abnorm Child Psychol. 2007;35(3):393-404.
37. Advokat C, Martino L, Hill BD, Gouvier W. Continuous Performance Test (CPT) of college students with ADHD, psychiatric disorders, cognitive deficits, or no diagnosis. J Atten Disord. 2007;10(3):253-256.
38. Preston AS, Fennell EB, Bussing R. Utility of a CPT in diagnosing ADHD among a representative sample of high-risk children: a cautionary study. Child Neuropsychol. 2005;11(5):459-469.
39. Teicher MH, Lowen SB, Polcari A, Foley M, McGreenery CE. Novel strategy for the analysis of CPT data provides new insight into the effects of methylphenidate on attentional states in children with ADHD. J Child Adolesc Psychopharmacol. 2004;14(2):219-232.
40. Teicher MH, Polcari A, McGreenery CE. Utility of objective measures of activity and attention in the assessment of therapeutic response to stimulants in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2008;18(3):265-270.
41. Teicher MH, Polcari A, Foley M, et al. Methylphenidate blood levels and therapeutic response in children with attention-deficit hyperactivity disorder: I. Effects of different dosing regimens. J Child Adolesc Psychopharmacol. 2006;16(4):416-431.
42. Teicher MH, Ito Y, Glod CA, Barber NI. Objective measurement of hyperactivity and attentional problems in ADHD. J Am Acad Child Adolesc Psychiatry. 1996;35(3):334-342.
43. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994.
44. Orvaschel H, Puig-Antich J. Schedule for Affective Disorders and Schizophrenia for School-Age Children, Epidemiologic Version, 5th Revision. Fort Lauderdale, FL: Nova Southeastern University; 1994.
45. Faedda GL, Teicher MH. Objective measures of activity and attention in the differential diagnosis of psychiatric disorders of childhood. Essent Psychopharmacol. 2005;6(5):239-249.
46. Heiser P, Frey J, Smidt J, et al. Objective measurement of hyperactivity, impulsivity, and inattention in children with hyperkinetic disorders before and after treatment with methylphenidate. Eur Child Adolesc Psychiatry. 2004;13(2):100-104.
47. Faries DE, Yalcin I, Harder D, Heiligenstein JH. Validation of the ADHD rating scale as a clinician administered and scored instrument. J Atten Disord. 2001;5:107-115.
48. Guy W. ECDEU: Assessment Manual for Psychopharmacology, Revised. Rockville, MD: US Department of Health, Education, and Welfare; 1976.
49. Pliszka S; Work Group on Quality Issues. AACAP Official Action. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Child Adolesc Psychiatry. 2007;46(7):894-921.
50. Conners CK, Sitarenios G, Parker JD, Epstein JN. The revised Conners' Parent Rating Scale (CPRS-R): factor structure, reliability, and criterion validity. J Abnorm Child Psychol. 1998;26(4):257-268.
51. Newcorn JH, Sutton VK, Weiss MD, Sumner CR. Clinical responses to atomoxetine in attention-deficit/hyperactivity disorder: the Integrated Data Exploratory Analysis (IDEA) study. J Am Acad Child Adolesc Psychiatry. 2009;48(5):511-518.
52. Steele M, Jensen PS, Quinn DM. Remission versus response as the goal of therapy in ADHD: a new standard for the field? Clin Ther. 2006;28(11):1892-1908.
53. Lin LI. A concordance correlation coefficient to evaluate reproducibility. Biometrics. 1989;45(1):255-268.
54. Pelham WE Jr, Fabiano GA, Massetti GM. Evidence-based assessment of attention deficit hyperactivity disorder in children and adolescents. J Clin Child Adolesc Psychol. 2005;34(3):449-476.
55. Nichols SL, Waschbusch DA. A review of the validity of laboratory cognitive tasks used to assess symptoms of ADHD. Child Psychiatry Hum Dev. 2004;34(4):297-315.
56. Barkley RA. The ecological validity of laboratory and analogue assessment methods of ADHD symptoms. J Abnorm Child Psychol. 1991;19(2):149-178.
57. Conners CK, Epstein JN, Angold A, Klaric J. Continuous performance test performance in a normative epidemiological sample. J Abnorm Child Psychol. 2003;31(5):555-562.
58. Conners CK. The computerized continuous performance test. Psychopharmacol Bull. 1985;21(4):891-892.
59. Kelsey DK, Sumner CR, Casat CD, et al. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics. 2004;114(1):e1-e8.
60. Spencer TJ, Wilens TE, Biederman J, Weisler RH, Read SC, Pratt R. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2006;28(2):266-279.
61. Findling RL, Bukstein OG, Melmed RD, et al. A randomized, double-blind, placebo-controlled, parallel-group study of methylphenidate transdermal system in pediatric patients with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2008; 69(1):149-159.